Drug treatment in dementia

被引:7
作者
Bullock, R [1 ]
机构
[1] Victoria Hosp, Kingshill Res Ctr, Swindon SN1 4HZ, Wilts, England
关键词
D O I
10.1097/00001504-200107000-00019
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
The present review examines the current issues involving the use of drugs in the treatment of the various dementia syndromes, With the introduction of a new cholinesterase inhibitor, galantamine, during 2000, a recap of the symptomatic treatment issues reported during the past year leads on to early attempts at disease modification. Observational reports of the effect of oestrogen and anti-inflammatory drugs have led to therapeutic trials, which have mostly been negative, This may be due to incomplete understanding of mechanism and inappropriate trial design. Statins and vitamin E have been reported as beneficial, and an amyloid vaccine has entered into a clinical trial. The review finishes with some published experience in treating behavioural components of the dementia syndrome, and overall demonstrates how our understanding of the treatment issues continues to unfold. Curr Opin Psychiatry 14:349-353. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:349 / 353
页数:5
相关论文
共 56 条
  • [41] β-peptide immunization -: A possible new treatment for Alzheimer disease
    Schenk, DB
    Seubert, P
    Lieberburg, I
    Wallace, J
    [J]. ARCHIVES OF NEUROLOGY, 2000, 57 (07) : 934 - 936
  • [42] SCHENK DB, 1999, NATURE, V53, P438
  • [43] Estrogen and Alzheimer disease - Plausible theory, negative clinical trial
    Shaywitz, BA
    Shaywitz, SE
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (08): : 1055 - 1056
  • [44] Olanzapine use in the elderly: A retrospective analysis
    Solomons, K
    Geiger, O
    [J]. CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2000, 45 (02): : 151 - 155
  • [45] VITAMIN-E PLUS ASPIRIN COMPARED WITH ASPIRIN ALONE IN PATIENTS WITH TRANSIENT ISCHEMIC ATTACKS
    STEINER, M
    GLANTZ, M
    LEKOS, A
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 1995, 62 (06) : 1381 - 1384
  • [46] Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities -: A double-blind, randomized, placebo-controlled trial
    Street, JS
    Clark, WS
    Gannon, KS
    Cummings, JL
    Bymaster, FP
    Tamura, RN
    Mitan, SJ
    Kadam, DL
    Sanger, TM
    Feldman, PD
    Tollefson, GD
    Breier, A
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 2000, 57 (10) : 968 - 976
  • [47] Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease
    Tang, MX
    Jacobs, D
    Stern, Y
    Marder, K
    Schofield, P
    Gurland, B
    Andrews, H
    Mayeux, R
    [J]. LANCET, 1996, 348 (9025) : 429 - 432
  • [48] A 5-month, randomized, placebo-controlled trial of galantamine in AD
    Tariot, PN
    Solomon, PR
    Morris, JC
    Kershaw, P
    Lilienfeld, S
    Ding, C
    [J]. NEUROLOGY, 2000, 54 (12) : 2269 - 2276
  • [49] Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease
    Thal, LJ
    Forrest, M
    Loft, H
    Mengel, H
    [J]. NEUROLOGY, 2000, 54 (02) : 421 - 426
  • [50] Extended-release physostigmine in Alzheimer disease -: A multicenter, double-blind, 12-week study with dose enrichment
    van Dyck, CH
    Newhouse, P
    Falk, WE
    Mattes, JA
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 2000, 57 (02) : 157 - 164